Por: ABC News Tech July 05, 2023
BRUSSELS -- The European Union took a step Wednesday toward adapting its production to the new ways of the world: The 27-nation bloc wants to embrace the latest gene techniques it hopes will help safely counter global challenges like climate change and shortages. For decades, the EU was conservative in allowing the use of genetically modified organisms — which often brought up connotations of Frankenfood rather than improved crop production... + full article
Time USA Health June 23, 2023
For genetic conditions like Duchenne muscular dystrophy, there is little doctors can do to slow or treat the condition other than trying to manage symptoms, since only addressing the genetic changes responsible can help halt the disease. Earlier today (June 22), the U.S. Food... + más
First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids | ABC News
First gene therapy for deadly form of muscular dystrophy gets FDA approval for young kids | WPLG Local 10
The Boston Globe USA Business June 21, 2023
Ultragenyx Pharmaceutical, the San Francisco Bay Area-based biopharmaceutical company, on Wednesday officially opened a 110,000-square-foot plant in Bedford to manufacture gene therapies, one of the most innovative but expensive approaches to treat serious inherited... + más
Gene therapy has made some recent progress—is it enough? | Ars Technica
With South Coast Rail finally in view, New Bedford floats lawsuit claiming MBTA wrongly seized its land | The Boston Globe
The Boston Globe USA Business May 13, 2023
An panel of advisers Friday recommended that the Food and Drug Administration speed up approving a Duchenne muscular dystrophy treatment developed by Cambridge biotech Sarepta Therapeutics, despite questions about its clinical benefit and safety.By an 8 to 6 vote, the FDA... + más
Under pressure from patients, FDA faces tough choices on experimental gene therapy | The Boston Globe
FDA delays decision on Sarepta’s controversial gene therapy for muscular dystrophy | The Boston Globe
Forbes USA Tech March 11, 2023
Genetic engineeering concept with 3d rendering dna helix and a part of dnagetty This article is the eighth installment in my series on Alzheimer’s disease. Read more about Alzheimer’s disease in , , , , , , and of the series. If you are a person who has inherited the APOE4... + más
A Promising Trial Targets a Genetic Risk for Alzheimer’s | The New York Times
Chris Hemsworth discovers he may be at risk for Alzheimer’s disease in new series, ‘Limitless’ | ABC News
Ars Technica USA Science January 05, 2023
Navigate Filter by topic Settings Front page layout Site theme - Jan 5, 2023 12:45 pm UTC MARK GARLICK/SCIENCE PHOTO LIBRARY Share this story Gene therapy has had a long and bumpy history. Although researchers have made some notable and Despite these issues, experts say there... + más
Opinion | The New York Times
First participant in test of custom gene editing therapy dies | The Boston Globe
The Boston Globe USA Nation December 29, 2022
A new coronavirus variant dubbed XBB has swiftly spreading in the Northeast, jumping from about 35 percent of cases during the week ending Dec. 17 to just over half of cases last week, according to .Here’s a quick primer on what we know about the variant.It is more... + más
Highly Immune Evasive Omicron XBB.1.5 Variant Is Quickly Becoming Dominant in U.S. as It Doubles Weekly | NBC 6 South Florida
Highly immune evasive omicron XBB.1.5 variant is quickly becoming dominant in U.S. as it doubles weekly | CNBC
The New York Times USA Opinion December 09, 2022
The parents of a 2-year-old girl write that their daughter “could die within the next year” because a genetic mutation is causing her heart to fail.“Time is quickly running out for me,” writes a man in his mid-30s whose DNA harbors a genetic mistake certain to destroy... + más
Justice Alito accused of being SCOTUS leaker after new report: Disgrace | Newsweek
Why would Mac Jones get a second opinion on his injury, and how common is that? | The Boston Globe
About iurex | Privacy Policy | Disclaimer |